or Try an Advanced Search...

    Technical Analysis for KALA - Kala Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    B 6.99 -0.71% -0.05
    KALA closed down 0.71 percent on Friday, November 1, 2024, on 81 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical KALA trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Pocket Pivot Bullish Swing Setup -0.71%
    Calm After Storm Range Contraction -0.71%
    NR7 Range Contraction -0.71%
    NR7-2 Range Contraction -0.71%
    Wide Bands Range Expansion -0.71%
    Older End-of-Day Signals for KALA ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 20 hours ago
    Down 1% about 20 hours ago
    Possible NR7 about 21 hours ago
    60 Minute Opening Range Breakdown about 22 hours ago
    2x Volume Pace 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    KALA Chart by TradingView
    Basic chart:

    Profile

    Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Pain Organ Systems Eye Inflammation Ophthalmic Macular Degeneration Tyrosine Kinase Retina Wet Age Related Macular Degeneration Glucocorticoids Receptor Tyrosine Kinase Retinal Disease Blepharitis Post Surgical Ocular Inflammation

    Is KALA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Aug 8 KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
    Aug 6 KALA BIO GAAP EPS of -$3.16 beats by $1.25
    Aug 6 KALA BIO GAAP EPS of -$3.16
    Aug 6 KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    Jun 27 Kala Pharmaceuticals to sell 1.197M shares at $5.85 in private placement
    Jun 27 KALA BIO Announces $12,500,000 Private Placement
    May 29 KALA BIO to Present at Jefferies Global Healthcare Conference
    May 21 Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)
    May 14 Kala Pharmaceuticals GAAP EPS of -$4.20
    May 14 KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
    See more KALA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 10.97
    52 Week Low 4.21
    Average Volume 15,202
    200-Day Moving Average 6.60
    50-Day Moving Average 5.81
    20-Day Moving Average 5.89
    10-Day Moving Average 6.54
    Average True Range 0.35
    RSI (14) 70.33
    ADX 36.23
    +DI 30.97
    -DI 9.17
    Chandelier Exit (Long, 3 ATRs) 6.18
    Chandelier Exit (Short, 3 ATRs) 6.01
    Upper Bollinger Bands 7.50
    Lower Bollinger Band 4.28
    Percent B (%b) 0.84
    BandWidth 54.76
    MACD Line 0.40
    MACD Signal Line 0.22
    MACD Histogram 0.1807
    Fundamentals Value
    Market Cap 18.82 Million
    Num Shares 2.69 Million
    EPS -22.38
    Price-to-Earnings (P/E) Ratio -0.31
    Price-to-Sales 1.16
    Price-to-Book 1.77
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.32
    Resistance 3 (R3) 7.32 7.21 7.27
    Resistance 2 (R2) 7.21 7.13 7.21 7.25
    Resistance 1 (R1) 7.10 7.07 7.05 7.10 7.23
    Pivot Point 6.99 6.99 6.96 6.99 6.99
    Support 1 (S1) 6.88 6.91 6.82 6.88 6.75
    Support 2 (S2) 6.77 6.85 6.77 6.73
    Support 3 (S3) 6.66 6.77 6.71
    Support 4 (S4) 6.66